RLAY RELAY THERAPEUTICS INC Product Launches 8-K Filing 2024 - Clinical Data Release Relay Therapeutics announced interim clinical data for RLY-2608, a treatment for advanced breast cancer, showing a median progression-free survival of 9.2 months and a clinical benefit rate of 57% among patients treated with the recommended dose. The company plans to discuss these findings in a conference call on September 9, 2024.Get access to all SEC 8-K filings of the RELAY THERAPEUTICS INC